ConductScience.org, home

Paper3390835

Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study.

Kune GA and 2 others. Cancer Res, 1988. Cited by 641 papers, by iCite.

Cite this record

ConductScience Library. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Papers, record 3390835. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3390835

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study.
PubMed
Journal
Cancer Res
PubMed
Year
1988
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
641
iCite
Relative citation ratio, by iCite
17
iCite
Revised in PubMed
2022-03-11
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kune GAG A
2Kune SS
3Watson LFL F

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Colonic NeoplasmsMajor topic
Epidemiologic MethodsMajor topic
Rectal NeoplasmsMajor topic
Aged
Australia
Chronic Disease
Combined Modality Therapy
Female
Humans
Male
Middle Aged
Risk Factors

Source PubMed

Download CSV of topics

Cited by181

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 641 citations.

PMIDTitleJournalYearIn PapersSource
42626236Cyclooxygenases in pancreatic ductal adenocarcinoma: are they inflammatory catalysts for tumor growth.Front Oncol2026https://conductscience.org/library/papers/42626236PubMed
41508334Aspirin for hepatocellular carcinoma prevention in MASLD: How far are we ready to proceed?: Editorial on "Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis".Clin Mol Hepatol2026https://conductscience.org/library/papers/41508334PubMed
40619604Precision Prevention Studies: A Targeted Approach to Cancer Prevention.Cancer Prev Res (Phila)2025https://conductscience.org/library/papers/40619604PubMed
40573208Chemoprevention of Colorectal Cancer-With Emphasis on Low-Dose Aspirin and Anticoagulants.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40573208PubMed
40285986NSAID-encapsulated nanoparticles as a targeted therapeutic platform for modulating chronic inflammation and inhibiting cancer progression: a review.Inflammopharmacology2025https://conductscience.org/library/papers/40285986PubMed
39766102The Potential Therapeutic Value of Aspirin in Anaplastic Thyroid Cancer.Cancers (Basel)2024https://conductscience.org/library/papers/39766102PubMed
39600254Type II diabetes and metformin use does not affect colorectal cancer prognosis.Int J Cancer2025https://conductscience.org/library/papers/39600254PubMed
39546469Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome.JCO Precis Oncol2024https://conductscience.org/library/papers/39546469PubMed
39445288Exploring Aspirin's Potential in Cancer Prevention: A Comprehensive Review of the Current Evidence.Cureus2024https://conductscience.org/library/papers/39445288PubMed
39064188Aspirin in Primary Prevention: Looking for Those Who Enjoy It.J Clin Med2024https://conductscience.org/library/papers/39064188PubMed
38791445Harnessing Oxylipins and Inflammation Modulation for Prevention and Treatment of Colorectal Cancer.Int J Mol Sci2024https://conductscience.org/library/papers/38791445PubMed
38675399The 125th Anniversary of Aspirin-The Story Continues.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/38675399PubMed
38106409Decoding the role of platelets in tumour metastasis: enigmatic accomplices and intricate targets for anticancer treatments.Front Immunol2023https://conductscience.org/library/papers/38106409PubMed
38064111Using aspirin to prevent and treat cancer.Inflammopharmacology2024https://conductscience.org/library/papers/38064111PubMed
37663811Metformin and Aspirin: Anticancer effects on A549 and PC3 cancer cells and the mechanisms of action.Toxicol Res (Camb)2023https://conductscience.org/library/papers/37663811PubMed
37513924The Effect of Acetylsalicylic Acid, as a Representative Non-Steroidal Anti-Inflammatory Drug, on the Activity of Myeloperoxidase.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/37513924PubMed
37221467An integrative review of nonobvious puzzles of cellular and molecular cardiooncology.Cell Mol Biol Lett2023https://conductscience.org/library/papers/37221467PubMed
37108226Molecular Ultrasound Imaging Depicts the Modulation of Tumor Angiogenesis by Acetylsalicylic Acid.Int J Mol Sci2023https://conductscience.org/library/papers/37108226PubMed
36647071Aspirin increases chemosensitivity of colorectal cancer cells and inhibits the expression of toll-like receptor 4.Cancer Cell Int2023https://conductscience.org/library/papers/36647071PubMed
36189951Fifty years with aspirin and platelets.Br J Pharmacol2023https://conductscience.org/library/papers/36189951PubMed

See all 181 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3390835

GET https://conductscience.org/api/papers/v1/3390835/cited_by?page=2